drugset / Trial / NCT06508229
Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, single-arm, phase II clinical study designed to observe and evaluate the effectiveness and safety of adebrelimab combined with albumin paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma.
Timeline
- Start
- 2024-07-30
- Primary completion
- 2027-05-30
- Completion
- 2028-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | Intravenous |
| Subject | Albumin paclitaxel | Unknown | — | Intravenous |
| Subject | Nedaplatin | Small molecule | — | Intravenous |